DCDS4501A: Interim Phase I data

Interim data from 33 heavily pretreated patients in a dose-escalation Phase I trial showed that the recommended Phase II dose of IV DCDS4501A was 2.4 mg/kg given every 21 days. There was 1 patient with a dose-limiting toxicity (DLT) of grade 4 febrile neutropenia and pneumonia. Furthermore, 2 of 4 evaluable patients receiving 2.4 mg/kg IV DCDS4501A had a >80% reduction in target lesion burden. Grade 4 febrtile neutropenia and pneumonia was the DLT at the 2.4 mg/kg dose. The most common adverse events reported were neutropenia, diarrhea, nausea, hyperglycemia, fatigue, constipation, peripheral neuropathy, pyrexia, leucopenia, chills and cough. Data will be presented at the American Society of Hematology meeting in Atlanta in December. ...